JC124

JC124 is a specific NLRP3 inflammasome inhibitor. JC124 has anti-inflammatory and neuroprotective effects. In Vitro JC124 shows selective inhibition of NLRP3 inflammasome formation and activation of caspase-1, and reduction of IL-1β both in vitro. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo JC124 (100 mg/kg; i.p.; 4 doses; 30 min post-injury, 6, 24, and 30 h after TBI) treatment significantly decreases the number of injury-induced degenerating neurons, inflammatory cell response in the injured brain, and cortical lesion volume. JC124 also significantly reduces protein expression levels of NLRP3, ASC, IL-1 beta, TNFα, iNOS, and caspase-1 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Adult male Sprague-Dawley rats (3-4-months-old) bearing traumatic brain injury (TBI) Dosage: 100 mg/kg Administration: i.p.; 4 doses; 30 min post-injury, 6, 24, and 30 h after TBI Result: Significantly decreased the number of injury-induced degenerating neurons, inflammatory cell response in the injured brain, and cortical lesion volume. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet